Online inquiry

IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11309MR)

This product GTTS-WQ11309MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ITGAV&ITGB3 gene. The antibody can be applied in Sarcoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001144999.3; NM_000212.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3685; 3690
UniProt ID P06756; P05106
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ11309MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6999MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA F-627
GTTS-WQ9093MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMCgp100
GTTS-WQ5353MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ10327MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LJM716
GTTS-WQ744MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ14463MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RO-7105705
GTTS-WQ123MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 11F8
GTTS-WQ2726MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-139
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW